Human IFN-γ T cell ELISPOT antibody pair - 10-plate

SKU
CT640-10
Validated ELISPOT antibody pair; reagents available separately (960 determinations).
Format
10-plate
Price
€ 655
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT antibody pairs are validated for high assay performance using the same reagents and materials included in U-CyTech ELISPOT kits. These antibody pairs are optimized for reliable and reproducible ELISPOT assays.
The antibody pairs are available in convenient 10-plate and 20-plate format, providing 960 or 1920 determinations, respectively.
Compatible reagents for ELISPOT assays can be purchased separately, allowing customization of your ELISPOT workflow.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Image

References

Authors, et al. Title Journal Year Volume Pages
Ania Skowera CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope J Clin Invest 2008 118 3390-402
Jeroen Gerrits Donor-reactive cytokine profiles after HLA-identical living-related kidney transplantation Nephrol Dial Transplant 2008 23 2016-23
V Huurman Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes Clin Exp Immunol 2008 152 488-97
Srinath Sanda Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes Clin Immunol 2008 127 138-43
Emanuela Martinuzzi The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment Diabetes 2008 57 1312-20
Emanuela Martinuzzi Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection J Immunol Methods 2008 333 61-70
Nicole van Besouw After discontinuation of calcineurin inhibitors, tapering of mycophenolate mofetil further impairs donor-directed cytotoxicity Clin Transplant 2008 22 129-35
Jiang Li Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy PLoS One 2007 2 e1122
Philippe Blancou Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients J Immunol 2007 178 7458-66
Jingxue Wang Lewis X oligosaccharides targeting to DC-SIGN enhanced antigen-specific immune response Immunology 2007 121 174-82